Completed PHASE1 INTERVENTIONAL NCT00336765

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors

Sponsor: Kadmon Corporation, LLC

Conditions Cancer

Interventions XL647

Updated 7 times since 2017 Last updated: May 9, 2022 Started: Jul 31, 2006 Primary completion: Aug 31, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cancer and is currently completed. Kadmon Corporation, LLC leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jun 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kadmon Corporation, LLC

Data source: Kadmon Corporation, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States
• Stanford, United States